Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with hypertension have a high prevalence of concurrent metabolic abnormalities, including obesity, dyslipidemia, and hyperglycemia. Clustering of these cardiovascular risk factors, defined as metabolic syndrome, causes a more pronounced target organ damage. Aldosterone excess has been found to be associated with glucose disorders and may contribute to cardiovascular damage. OBJECTIVE: The aim of our study was to assess the prevalence and the characteristics of the metabolic syndrome in a group of patients with hypertension due to primary aldosteronism compared with patients with essential hypertension. METHODS: The National Cholesterol Education Program Adult Treatment Panel III definition of the metabolic syndrome was used. Eighty-five patients with primary aldosteronism and 381 patients with essential hypertension were studied. Most patients were not receiving antihypertensive therapy during the investigation. RESULTS: Blood glucose and systolic blood pressure were higher (P < 0.05 and P < 0.01, respectively) and duration of hypertension was longer (P < 0.05) in primary aldosteronism than in essential hypertension. The prevalence of metabolic syndrome was higher in primary aldosteronism than in essential hypertension (41.1% vs. 29.6%; P < 0.05). Distribution of single components of the metabolic syndrome other than hypertension showed a higher prevalence of hyperglycemia in primary aldosteronism than in essential hypertension (27.0% vs. 15.2%; P < 0.05). CONCLUSIONS: Our findings confirm a negative effect of aldosterone excess on glucose metabolism and suggest that the recently reported higher rates of cardiovascular events in primary aldosteronism than in essential hypertension might be due to increased prevalence of the metabolic syndrome in the former condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [6]
In the citing paper
“Higher plasma mineralocorticoid levels may be associated with IR (, ).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [166]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.7.1514 · Cited by 1,516
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., & Fuchs, Z. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111776 · Cited by 1,465
Cited by
Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30319-4 · Cited by 1,072
Self-citationPrevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice
Monticone, S., Burrello, J., Tizzani, D., Bertello, C., Viola, A., Buffolo, F., Gabetti, L., Mengozzi, G., Williams, T. A., Rabbia, F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.052 · Cited by 882
Self-citationPrimary aldosteronism: renaissance of a syndrome
Young, W. F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02775.x · Cited by 680
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
Pivotal role of the mineralocorticoid receptor in corticosteroid‐induced adipogenesis
Caprio, M., Fève, B., Claës, A., Viengchareun, S., Lombès, M., & Zennaro, M.-C. (2007) · The FASEB Journal · doi:10.1096/fj.06-7970com · Cited by 337
“compared to patients with essential hypertension (28).”
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, W. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12831 · Cited by 325
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Cooper, S. A., Whaley-Connell, A., Habibi, J., Wei, Y., Lastra, G., Manrique, C., Stas, S., & Sowers, J. R. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00522.2007 · Cited by 317
“primary aldosteronism is related to impaired glucose homeostasis (52), as well as insulin resistance (28).”
BackgroundVaidya, A., Mulatero, P., Baudrand, R., & Adler, G. K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00139 · Cited by 299
Self-citationSteroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
Insulin Sensitivity in Patients with Primary Aldosteronism: A Follow-Up Study
Catena, C., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G., Novello, M., Favret, G., Melis, A., Cavarape, A., & Sechi, L. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0736 · Cited by 262
Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2116 · Cited by 261
“In addition, recent data have suggested that higher rates of cardiovascular events in PA might be due to an increased prevalence of the metabolic syndrome in PA (34).”
BackgroundConvertible visceral fat as a therapeutic target to curb obesity
Giordano, A., Frontini, A., & Cinti, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.31 · Cited by 232
Primary aldosteronism: diagnostic and treatment strategies
Mattsson, C., & Young, W. F. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0151 · Cited by 219
“Although its pathogenesis is unclear, the metabolic syndrome is more common among patients with primary aldosteronism than among patients with essential hypertension”
BackgroundBody Mass Index Predicts Aldosterone Production in Normotensive Adults on a High-Salt Diet
Bentley-Lewis, R., Adler, G. K., Perlstein, T., Seely, E. W., Hopkins, P. N., Williams, G. H., & Garg, R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1088 · Cited by 212
“with insulin resistance (4, 5), and treatment of primary hyperaldosteronism has been shown to reduce insulin resistance (6).”
BackgroundPrimary aldosteronism — a multidimensional syndrome
Turcu, A. F., Yang, J., & Vaidya, A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00730-2 · Cited by 189
Primary aldosteronism: cardiovascular, renal and metabolic implications
Rossi, G.-P., Sechi, L. A., Giacchetti, G., Ronconi, V., Strazzullo, P., & Funder, J. W. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.01.006 · Cited by 204
Ohno, Y., Sone, M., Inagaki, N., Yamasaki, T., Ogawa, O., Takeda, Y., Kurihara, I., Itoh, H., Umakoshi, H., Tsuiki, M., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10263 · Cited by 198
Rossi, G. P., Belfiore, A., Bernini, G., Fabris, B., Caridi, G., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0251 · Cited by 188
“Of note, PA has been associated with an increased prevalence of the metabolic syndrome, which includes abdominal adiposity ( 24 , 25).”
BackgroundArmani, A., Cinti, F., Marzolla, V., Morgan, J., Cranston, G. A., Antelmi, A., Carpinelli, G., Canese, R., Pagotto, U., Quarta, C., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-245415 · Cited by 166
Mulatero, P., Bertello, C., Rossato, D., Mengozzi, G., Milan, A., Garrone, C., Giraudo, G., Passarino, G., Garabello, D., Verhovez, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2055 · Cited by 178
Self-citationPrimary Aldosteronism: Practical Approach to Diagnosis and Management
Byrd, J. B., Turcu, A. F., & Auchus, R. J. (2018) · Circulation · doi:10.1161/circulationaha.118.033597 · Cited by 169
Tomaschitz, A., Ritz, E., Pieske, B., Rus-Machan, J., Kienreich, K., Verheyen, N., Gaksch, M., Grübler, M., Fahrleitner-Pammer, A., Mrak, P., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2013.08.016 · Cited by 166
“[79] Fallo F,Veglio F, Bertello C, et al.”
Stowasser, M., & Gordon, R. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00026.2015 · Cited by 159
“Fallo and co-workers, having previously reported metabolic syndrome (and in particular hyperglycemia) to be more prevalent among patients with PA than in essential hypertensives (139), more recently found both higher levels of insulin resistance, defined by the homeostasis model assessment index, and lower adiponectin…”
ResultRole of Heme Oxygenase in Inflammation, Insulin-Signalling, Diabetes and Obesity
Ndisang, J. F. (2010) · Mediators of Inflammation · doi:10.1155/2010/359732 · Cited by 172
Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension
Whaley‐Connell, A. T., Johnson, M. S., & Sowers, J. R. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.12.004 · Cited by 170
Hanslik, G., Wallaschofski, H., Dietz, A., Riester, A., Reincke, M., Allolio, B., Lang, K., Quack, I., Rump, L. C., Willenberg, H. S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0450 · Cited by 155
Mulatero, P., Bertello, C., Sukor, N., Gordon, R., Rossato, D., Daunt, N., Leggett, D., Mengozzi, G., Veglio, F., & Stowasser, M. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.146613 · Cited by 149
Self-citationObesity, proteinuria and progression of renal failure
Praga, M., & Morales, E. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000242172.06459.7c · Cited by 145
“A recent study [ 27 ] showed that the prevalence of metabolic syndrome was significantly higher in primary aldosteronism than in essential hypertension (41% compared with 29%).”
BackgroundPrimary Aldosteronism: State-of-the-Art Review
Vaidya, A., Hundemer, G. L., Nanba, K., Parksook, W. W., & Brown, J. M. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac079 · Cited by 150
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Shibata, H., & Itoh, H. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2011.245 · Cited by 140
Intrarenal Hemodynamics in Primary Aldosteronism before and after Treatment
Sechi, L. A., Fabio, A. D., Bazzocchi, M., Uzzau, A., & Catena, C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2245 · Cited by 137
Williams, T. A., & Reincke, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0990 · Cited by 141
Letavernier, E., Peyrard, S., Amar, L., Zinzindohoué, F., Fiquet, B., & Plouin, P.-F. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283060f0c · Cited by 121
Role of KCNJ5 in familial and sporadic primary aldosteronism
Mulatero, P., Monticone, S., Rainey, W. E., Veglio, F., & Williams, T. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.230 · Cited by 133
“Augusta/Dallas (US) 16 (5) 31 0 100 – 36”
Self-citationInappropriate Left Ventricular Mass in Patients With Primary Aldosteronism
Muiesan, M. L., Salvetti, M., Paini, A., Agabiti-Rosei, C., Monteduro, C., Galbassini, G., Belotti, E., Aggiusti, C., Rizzoni, D., Castellano, M., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.114140 · Cited by 126
Update in Primary Aldosteronism
Stowasser, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3663 · Cited by 126
Hoppmann, J., Perwitz, N., Meier, B., Faßhauer, M., Hadaschik, D., Lehnert, H., & Klein, J. C. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0292 · Cited by 131
Matrozova, J., Steichen, O., Amar, L., Zacharieva, S., Jeunemaître, X., & Plouin, P. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.122002 · Cited by 129
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome
Cascella, T., Palomba, S., Tauchmanovà, L., Manguso, F., Di Biase, S., Labella, D., Giallauria, F., Vigorito, C., Colao, A., Lombardi, G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0399 · Cited by 120
“the absence of the metabolic syndrome in that study (19).”
BackgroundInfluentialLastra, G., Whaley-Connell, A., Manrique, C., Habibi, J., Gutweiler, A. A., Appesh, L., Hayden, M. R., Wei, Y., Ferrario, C., & Sowers, J. R. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00258.2007 · Cited by 119
“In addition, aldosterone excess in patients with primary aldosteronism is related to impaired glucose homeostasis (11) as well as insulin resistance (9).”
BackgroundCardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment
Sechi, L. A., Colussi, G., Fabio, A. D., & Catena, C. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.169 · Cited by 122
Urbanet, R., Nguyen Dinh Cat, A., Feraco, A., Venteclef, N., El Mogrhabi, S., Sierra-Ramos, C., Alvarez de la Rosa, D., Adler, G. K., Quilliot, D., Rossignol, P., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04981 · Cited by 114
“tions suggests, however, that aldo could directly act on MR in adipose tissue.(5) Furthermore, it has been demonstrated that adipocytes produce aldo,(30) supporting a local paracrine MR”
BackgroundSelf-citationSpironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
Colussi, G., Catena, C., & Sechi, L. A. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283599b6a · Cited by 108
“Because of the demonstration that excess aldosterone is associated with a variety of cardiovascular [17,18], renal [19,20], and metabolic [21,22] sequelae that reflect the capability of aldosterone to induce organ damage over that induced by hypertension itself [23], this goal achieves specific relevance in patients w…”
BackgroundRelationships of Plasma Renin Levels with Renal Function in Patients with Primary Aldosteronism
Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., & Sechi, L. A. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00050107 · Cited by 117
Improving obesity and blood pressure
Tanaka, M. (2019) · Hypertension Research · doi:10.1038/s41440-019-0348-x · Cited by 121
Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
Gerards, J., Heinrich, D. A., Adolf, C., Meisinger, C., Rathmann, W., Sturm, L., Nirschl, N., Bidlingmaier, M., Beuschlein, F., Thorand, B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00299 · Cited by 112
Parasiliti‐Caprino, M., Lopez, C., Prencipe, N., Lucatello, B. G., Settanni, F., Giraudo, G., Rossato, D., Mengozzi, G., Ghigo, E., Benso, A. S., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002441 · Cited by 120
“Also in the unselected hypertensive population, some studies revealed impaired metabolic variables [3,26], high rate of diabetes mellitus [8–11,26] and metabolic syndrome [3,9,10,27,28], while other authors [7,29–34] did not show differences in metabolic variables and metabolic syndrome rate between primary aldosteron…”
ResultPsychological Assessment of Primary Aldosteronism: A Controlled Study
Sonino, N., Tomba, E., Genesia, M. L., Bertello, C., Mulatero, P., Veglio, F., Fava, G. A., & Fallo, F. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2723 · Cited by 106
Self-citationRisk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years
Wu, V.-C., Chueh, S.-C. J., Chen, L., Chang, C.-H., Hu, Y.-H., Lin, Y.-H., Wu, K.-D., & Yang, W.-S. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001361 · Cited by 107
“Insulin resistance and high prevalence of diabetes mellitus has been debated in patients with primary aldosteronism: reports ranging from no differences in indices of glucose metabolism and insulin resistance between primary aldosteronism patients and controls with essential hypertension [5] to increased prevalence of…”
BackgroundKrug, A. W., & Ehrhart‐Bornstein, M. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.109439 · Cited by 105
Adiponectin and Insulin Sensitivity in Primary Aldosteronism
FALLO, F., DELLAMEA, P., SONINO, N., BERTELLO, C., ERMANI, M., VETTOR, R., VEGLIO, F., & MULATERO, P. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.03.012 · Cited by 101
Self-citationThe Role of Aldosterone in the Metabolic Syndrome
Briet, M. B., & Schiffrin, E. L. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0182-2 · Cited by 101
“[36] demonstrated that patients with PA had a significantly higher prevalence of metabolic syndrome (defined by ATP III criteria) than patients with essential hypertension (41.”
BackgroundDiagnosis and treatment of low‐renin hypertension
Mulatero, P., Verhovez, A., Morello, F., & Veglio, F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02898.x · Cited by 111
Self-citationIs Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn's Registry
Reincke, M., Meisinger, C., Holle, R., Quinkler, M., Hahner, S., Beuschlein, F., Bidlingmaier, M., Seissler, J., & Endres, S. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1246189 · Cited by 98
Akehi, Y., Yanase, T., Motonaga, R., Umakoshi, H., Tsuiki, M., Takeda, Y., Yoneda, T., Kurihara, I., Itoh, H., Katabami, T., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1293 · Cited by 95
A possible association between primary aldosteronism and a lower β-cell function
Mosso, L. M., Carvajal, C. A., Maiz, A., Ortiz, E. H., Castillo, C. R., Artigas, R. A., & Fardella, C. E. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282861fa4 · Cited by 94
Biomarkers to Guide Medical Therapy in Primary Aldosteronism
Hundemer, G. L., Leung, A. A. C., Kline, G. A., Brown, J. M., Turcu, A. F., & Vaidya, A. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad024 · Cited by 97
Adipose tissue renin–angiotensin–aldosterone system (RAAS) and progression of insulin resistance
Marcus, Y., Shefer, G., & Stern, N. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.021 · Cited by 97
“Interference of aldosterone with insulin’s action may underlie the increased rate of the metabolic syndrome and aberrant glucose metabolism in PA reported in some, but not all, studies (Fallo et al., 2006; Giacchetti et al., 2007; Matrozova et al., 2009).”
ResultUpdate in Primary Aldosteronism
Stowasser, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1399 · Cited by 96
Role of aldosterone and angiotensin II in insulin resistance: an update
Lastra‐Lastra, G., Sowers, J. R., Restrepo‐Erazo, K., Manrique‐Acevedo, C., & Lastra‐González, G. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03498.x · Cited by 90
Diagnosis and management of primary aldosteronism
Vilela, L. A. P., & Almeida, M. Q. (2017) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000274 · Cited by 101
Aldosterone excess impairs first phase insulin secretion in primary aldosteronism
Fischer, E., Adolf, C., Pallauf, A., Then, C., Bidlingmaier, M., Beuschlein, F., Seissler, J., & Reincke, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3934 · Cited by 88
Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism
Karashima, S., Yoneda, T., Kometani, M., Ohe, M., Mori, S., Sawamura, T., Furukawa, K., Seta, T., Yamagishi, M., & Takeda, Y. (2015) · Hypertension Research · doi:10.1038/hr.2015.129 · Cited by 88
Mineralocorticoid Receptors in Metabolic Syndrome: From Physiology to Disease
Feraco, A., Marzolla, V., Scuteri, A., Armani, A., & Caprio, M. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.11.006 · Cited by 85
Fu, B., Zhang, X., Wang, G., Lang, B., Ma, X., Li, H., Wang, B., Shi, T., Ai, X., Zhou, H., et al. (2011) · The Journal of Urology · doi:10.1016/j.juro.2010.12.051 · Cited by 87
Mineralocorticoid receptors in the metabolic syndrome
Zennaro, M., Caprio, M., & Fève, B. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.05.006 · Cited by 88
Adipokines and Cardiometabolic Profile in Primary Hyperaldosteronism
Iacobellis, G., Petramala, L., Cotesta, D., Pergolini, M., Zinnamosca, L., Cianci, R., De Toma, G., Sciomer, S., & Letizia, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2204 · Cited by 80
The metabolic syndrome: Insulin resistance
Mikhail, N. E. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0027-4 · Cited by 85
“The latter fi nding is in accordance with data showing a higher prevalence of the metabolic syndrome in primary hyperaldosteronism than in essential hypertension (41% vs 30%) [ 13 ].”
ResultMitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor
Lefranc, C., Friederich‐Persson, M., Palacios, R., & Cat, A. N. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0163 · Cited by 84
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism
Ohno, Y., Sone, M., Inagaki, N., Yamasaki, T., Ogawa, O., Takeda, Y., Kurihara, I., Umakoshi, H., Ichijo, T., Katabami, T., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00866 · Cited by 82
Molecular mechanisms underlying metabolic syndrome: the expanding role of the adipocyte
Armani, A., Berry, A., Cirulli, F., & Caprio, M. (2017) · The FASEB Journal · doi:10.1096/fj.201601125rrr · Cited by 73
Marzolla, V., Armani, A., Feraco, A., Martino, M. U. D., Fabbri, A., Rosano, G. M. C., & Caprio, M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.001 · Cited by 79
“describes a higher prevalence of metabolic syndrome in patients with primary aldosteronism compared to patients with essential hypertension [12], with relevant differences in glucose metabolism between patient groups.”
BackgroundAngiotensin 1-7 as Means to Prevent the Metabolic Syndrome
Marcus, Y., Shefer, G., Sasson, K., Kohen, F., Limor, R., Pappo, O., Nevo, N., Biton, I., Bach, M., Berkutzki, T., et al. (2013) · Diabetes · doi:10.2337/db12-0792 · Cited by 75
“The prevalence of the MetSyn is higher in patients with primary hyperaldosteronism than in essential hypertension (47).”
BackgroundUmakoshi, H., Ogasawara, T., Takeda, Y., Kurihara, I., Itoh, H., Katabami, T., Ichijo, T., Wada, N., Shibayama, Y., Yoshimoto, T., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13582 · Cited by 77
Is Primary Aldosteronism Still Largely Unrecognized?
Buffolo, F., Monticone, S., Burrello, J., Tetti, M., Veglio, F., Williams, T. A., & Mulatero, P. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119755 · Cited by 77
“Subsequently it was shown that patients with PA present a higher rate of metabolic syndrome [8, 73, 74], higher levels of plasma fasting glucose, and a PA prevalence in primary care centers”
BackgroundSelf-citationPrimary Aldosteronism and Obstructive Sleep Apnea: A Cross-Sectional Multi-Ethnic Study
Buffolo, F., Li, Q., Monticone, S., Heinrich, D. A., Mattei, A., Pieroni, J., Mei, M., Yang, S., Hu, Y., Yang, M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13833 · Cited by 76
“Aldosterone excess can play a significant role in this complex interplay because it is associated with metabolic alterations including type 2 diabetes mellitus and play a significant role in patients with severe OSA by increasing BP and worsening upper airways congestion.(11,23,39) The strengths of our study are the l…”
BackgroundSelf-citationGenomic and rapid effects of aldosterone: what we know and do not know thus far
Hermidorff, M. M., de Assis, L. V. M., & Isoldi, M. C. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9591-2 · Cited by 75
The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism
Šomlóová, Z., Widimský, J., Rosa, J., Wichterle, D., Štrauch, B., Petrák, O., Zelinka, T., Vlková, J., Mašek, M., Dvořáková, J., et al. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.65 · Cited by 68
Aldosterone and Cardiovascular Disease
Gaddam, K. K., Pimenta, E., Husain, S., & Calhoun, D. A. (2009) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2008.10.002 · Cited by 76
Brown, J. M., Wijkman, M. O., Claggett, B. L., Shah, A. M., Ballantyne, C. M., Coresh, J., Grams, M. E., Wang, Z., Yu, B., Boerwinkle, E., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19134 · Cited by 68
Pizarro, M., Solís, N., Quintero, P., Barrera, F., Cabrera, D., Rojas‐de Santiago, P., Arab, J. P., Padilla, O., Roa, J. C., Moshage, H., et al. (2015) · Liver International · doi:10.1111/liv.12794 · Cited by 66
“In these models, inappropriate activation of MR has been also associated with diabetes and IR (28, 29) and MR antagonism significantly inhibited adipose tissue inflammation and improved systemic glucose metabolism also influencing liver steatosis and inflammation.”
MethodAldosterone and the Risk of Hypertension
Xanthakis, V., & Vasan, R. S. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0330-y · Cited by 65
The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
Baudrand, R. F., & Vaidya, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020546 · Cited by 68
Mineralocorticoid receptor activation in obesity hypertension
Nagase, M., & Fujita, T. (2009) · Hypertension Research · doi:10.1038/hr.2009.86 · Cited by 72
Primary Aldosteronism Diagnosis and Management
Hundemer, G. L., & Vaidya, A. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.002 · Cited by 76
Thuzar, M., Law, W. P., Dimeski, G., Stowasser, M., & Ho, K. K. Y. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13539 · Cited by 64
Aldosterone Production and Signaling Dysregulation in Obesity
Vecchiola, A., Lagos, C. F., Carvajal, C. A., Baudrand, R. F., & Fardella, C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0626-9 · Cited by 65
Biadgo, B., Melak, T., Ambachew, S., Baynes, H. W., Limenih, M. A., Jaleta, K. N., Tachebele, B., Melku, M., & Abebe, M. (2018) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v28i5.16 · Cited by 63
“aldosterone excess on glucose metabolism (13).”
Mineralocorticoid Antagonists Treatment Versus Surgery in Primary Aldosteronism
Catena, C., Colussi, G., Fabio, A. D., Valeri, M., Marzano, L. A., Uzzau, A., & Sechi, L. A. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1246185 · Cited by 62
Satoh, F., Ito, S., Itoh, H., Rakugi, H., Shibata, H., Ichihara, A., Omura, M., Takahashi, K., Okuda, Y., & Iijima, S. (2020) · Hypertension Research · doi:10.1038/s41440-020-00570-5 · Cited by 60
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension
Dudenbostel, T., Ghazi, L., Liu, M., Li, P., Oparil, S., & Calhoun, D. A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07806 · Cited by 60
“Likewise, metabolic syndrome has been shown to be more prevalent in obese patients with primary aldosteronism.(28) These factors and others are associated with pathological fat distribution and function and may play a role in the observed aldosterone dysregulation.”
BackgroundEndocrine Hypertension in Small Animals
Reusch, C. E., Schellenberg, S., & Wenger, M. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2009.10.005 · Cited by 68
Genetics of Aldosterone-Producing Adenoma in Korean Patients
Hong, A. R., Kim, J. H., Song, Y. S., Lee, K. E., Seo, S. H., Seong, M., Shin, C. S., Kim, S. W., & Kim, S. Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147590 · Cited by 59
Impact of Adrenal Steroids on Regulation of Adipose Tissue
Infante, M., Armani, A., Mammi, C., Fabbri, A., & Caprio, M. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160037 · Cited by 60
Association of plasma aldosterone with the metabolic syndrome in two German populations
Hannemann, A., Meisinger, C., Bidlingmaier, M., Döring, A., Thorand, B., Heier, M., Belcredi, P., Ladwig, K.-H., Wallaschofski, H., Friedrich, N., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1074 · Cited by 57
Caveolin 1 Modulates Aldosterone‐Mediated Pathways of Glucose and Lipid Homeostasis
Baudrand, R. F., Gupta, N., Garza, A., Vaidya, A., Leopold, J. A., Hopkins, P. N., Jeunemaître, X., Ferri, C., Romero, J. R., Williams, J. S., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003845 · Cited by 59
“aldosterone/MR activation with higher glycemia and lower HDL in participants both with and without primary hyperaldosteronism.(3,37,38) Furthermore, HDL maintains the proper lipid environment of caveolae,(39) thereby modulating the function of cav-1 and of the various enzymes and receptors in this microenvironment, in…”
BackgroundLastra, G., & Sowers, J. R. (2013) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0025 · Cited by 59
“In humans, markers of whole-body insulin resistance are elevated in the setting of primary aldosteronism, along with a higher prevalence of features of the metabolic syndrome including impaired carbohydrates tolerance [39, 40].”
Background
Metadata
- Authors
- Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G., & Mulatero, P.
- Affiliations
- University of Padua (IT)
- University of Turin (IT)
- Corresponding author
- Fallo, Francesco
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-02
- Volume
- 91
- Issue
- 2
- Pages
- 454-459
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2099583783
- Semantic Scholar
- 5b2795dc0ee3d66f4f0cf0367b9210dd5492663a
- Cited by
- 372
- References
- 61
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 16 · 2022: 14 · 2021: 16 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 23 · 2016: 18 · 2015: 17 · 2014: 17 · 2013: 22 · 2012: 23
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Università degli Studi di Padova
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, metabolic syndrome, essential hypertension, hyperglycemia, aldosterone excess, glucose metabolism, cardiovascular risk, dyslipidemia, obesity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Female, Humans, Hyperaldosteronism, Hypertension, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Triglycerides, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.